DK1128837T3 - Medikament til at foebygge og bevirke tilbagegang af atherosclerose hos pattedyr - Google Patents

Medikament til at foebygge og bevirke tilbagegang af atherosclerose hos pattedyr

Info

Publication number
DK1128837T3
DK1128837T3 DK99972104T DK99972104T DK1128837T3 DK 1128837 T3 DK1128837 T3 DK 1128837T3 DK 99972104 T DK99972104 T DK 99972104T DK 99972104 T DK99972104 T DK 99972104T DK 1128837 T3 DK1128837 T3 DK 1128837T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
aliquot
preventing
medication
mammals
Prior art date
Application number
DK99972104T
Other languages
English (en)
Inventor
Duncan J Stewart
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/304,262 external-priority patent/US6264646B1/en
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of DK1128837T3 publication Critical patent/DK1128837T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023Aggression treatment or altering
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electrotherapy Devices (AREA)
  • Radiation-Therapy Devices (AREA)
DK99972104T 1998-11-13 1999-11-15 Medikament til at foebygge og bevirke tilbagegang af atherosclerose hos pattedyr DK1128837T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19023698A 1998-11-13 1998-11-13
US09/304,262 US6264646B1 (en) 1998-11-13 1999-05-06 Method for preventing and reversing atherosclerosis in mammals
PCT/CA1999/001092 WO2000029003A2 (en) 1998-11-13 1999-11-15 Method for preventing and reversing atherosclerosis in mammals

Publications (1)

Publication Number Publication Date
DK1128837T3 true DK1128837T3 (da) 2003-06-16

Family

ID=26885899

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99972104T DK1128837T3 (da) 1998-11-13 1999-11-15 Medikament til at foebygge og bevirke tilbagegang af atherosclerose hos pattedyr

Country Status (16)

Country Link
EP (1) EP1128837B1 (da)
JP (1) JP2002529510A (da)
CN (1) CN1230182C (da)
AT (1) ATE233093T1 (da)
AU (1) AU768300B2 (da)
BR (1) BR9915270A (da)
CA (1) CA2348599A1 (da)
CZ (1) CZ20011642A3 (da)
DE (1) DE69905602T2 (da)
DK (1) DK1128837T3 (da)
EA (1) EA003421B1 (da)
ES (1) ES2192885T3 (da)
MX (1) MXPA01004801A (da)
NO (1) NO20012311L (da)
NZ (1) NZ511467A (da)
WO (1) WO2000029003A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2271190A1 (en) 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
ATE309807T1 (de) 1999-09-24 2005-12-15 Vasogen Ireland Ltd Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
CA2309417A1 (en) 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
WO2005097145A1 (en) * 2004-04-12 2005-10-20 Vasogen Ireland Limited Myocarditis treatment
WO2008000067A1 (en) * 2006-06-26 2008-01-03 Vasogen Ireland Limited Treatment of mild chronic heart failure in human patients
RU2475275C1 (ru) * 2011-08-08 2013-02-20 Государственное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ лечения облитерирующего атеросклероза артерий нижних конечностей
RU2475274C1 (ru) * 2011-08-09 2013-02-20 Государственное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ лечения атеросклероза артерий нижних конечностей
RU2475276C1 (ru) * 2011-08-09 2013-02-20 Государственное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ лечения облитерирующего атеросклероза артерий нижних конечностей

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD249143A3 (de) * 1985-03-20 1987-09-02 Ilmenau Tech Hochschule Vorrichtung zur physiologisch-therapeutisch wirksamen optischen bestrahlung koerpereigenen venenblutes
AU3506293A (en) * 1992-02-07 1993-09-03 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases

Also Published As

Publication number Publication date
CN1230182C (zh) 2005-12-07
CN1330549A (zh) 2002-01-09
EA003421B1 (ru) 2003-04-24
DE69905602D1 (de) 2003-04-03
EP1128837B1 (en) 2003-02-26
ES2192885T3 (es) 2003-10-16
ATE233093T1 (de) 2003-03-15
EP1128837A2 (en) 2001-09-05
NO20012311D0 (no) 2001-05-10
AU1145000A (en) 2000-06-05
EA200100543A1 (ru) 2001-10-22
BR9915270A (pt) 2003-12-30
WO2000029003A2 (en) 2000-05-25
CZ20011642A3 (cs) 2002-06-12
WO2000029003A3 (en) 2000-08-31
NZ511467A (en) 2002-12-20
CA2348599A1 (en) 2000-05-25
AU768300B2 (en) 2003-12-04
NO20012311L (no) 2001-07-02
JP2002529510A (ja) 2002-09-10
DE69905602T2 (de) 2003-10-09
MXPA01004801A (es) 2002-09-18

Similar Documents

Publication Publication Date Title
DE69923671D1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
EA199800667A1 (ru) Новые фенантридины
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
NO20000085L (no) Forbedrede fremgangsmåter og preparater for behandling av ereksjonsdysfunksjon hos menn
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
DK0986382T3 (da) RAF-kinasehæmmere
PT680963E (pt) ¬(hidroxifenilamino)-carbonil|-pirrois
DE69910045D1 (de) Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
DE69105587D1 (de) Vorverzerrungslinearisierer für Mikrowellenleistungsverstärker.
DK193788A (da) Fremgangsmaade til isolering af nucleinsyrer
BR9811099A (pt) Inibidores de urocinase
DE69832431D1 (de) N-Weg-RF-Leistungsaddierer/-verteiler
ATE224386T1 (de) Neue in 6-position substituierte phenanthridine
EA200100571A1 (ru) Комбинированный способ лечебного воздействия, включающий применение лучевой терапии и ингибитора циклооксигеназы-2(cox-2) для лечения неоплазии
ATE336509T1 (de) Verwendung von taci als antitumormittel
DK1128837T3 (da) Medikament til at foebygge og bevirke tilbagegang af atherosclerose hos pattedyr
NO20003848L (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
NO880786D0 (no) Lineariserer for mikroboelgeeffektforsterkere.
DE60330051D1 (de) Ittels mikrowellenbestrahlung
ES2107852T3 (es) Procedimiento para la obtencion de 1,4-butanodiol.
NO20016380L (no) Fremgangsmåte for å forhindre tumorvekst
EA199800058A1 (ru) Способ лечения доброкачественной гиперплазии предстательной железы, лекарственная форма для лечения доброкачественной гиперплазии, содержащая агонист мелатонина
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
DE60111519D1 (de) Chemische modifizierung von harn von säugern
ECSP961804A (es) Nuevos compuestos monociclicos de b -.lactama